Explore our resources by research/diagnostic specialty or content type
ALPCO specialists are leveraging their extensive expertise to create a growing collection of resources for your research and testing. Find resources that benefit your work using the handy filters.
Watch our video to learn more about the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and how you can now measure this incretin hormone with confidence.
https://www.youtube.com/watch?v=Chu3VhEEpt0&t=3s
The STELLUX® Chemi Active GLP-1 (7-36) amide ELISA features increased sensitivity to accurately quantify active GLP-1 (7-36) amide levels as low as 1.5 pg/mL with a 25 µL sample volume...
In support of IBS Awareness Month, we created this short video to share some important facts about IBS and spread the word about this incurable, debilitating disorder.
Be sure to like and share our video to show your support of IBS Awareness Month!
https://youtu.be/6K_55Bg922s
Quick Facts About IBS
IBS was described as early as 1849 by Dr. Cumming in the London Medical Gazette.1
...
The liver is vital to various metabolic functions including lipid and glucose metabolism. In order to maintain homeostasis, efficient gut-liver and adipose tissue-liver communications are needed1,2. Research indicates that obesity induced dysfunctions within these crosstalks can lead to imbalances in energy metabolism and contribute to the pathogenesis of metabolic diseases such as nonalcoholic...
Monoclonal antibody (mAbs) biologics have been used to treat inflammatory bowel disease (IBD) for 20 years1. Despite the successful use of biologics as therapies for Crohn’s disease (CD) and ulcerative colitis (UC), these diseases remain difficult to manage. As a result, patients and healthcare providers are met with many challenges when treating IBD with biologics such as variable drug respons...
Anti-TNF-alpha biologics have been proven to be effective treatments for autoimmune diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD)1. Rising healthcare costs as well as patent expirations, however, have prompted the development of biosimilars, such as the infliximab biosimilar CT-P131. The introduction of these drugs also presents the need for a better understand...
Multiple classes of biologics are available for the treatment of inflammation associated with inflammatory bowel disease (IBD) which ultimately improves the quality of life for patients. However, many challenges are associated with using biologics to treat IBD such as immunogenetic reactions and the rising cost of treatment1-4. These challenges are driving the need for more personalized and co...
Monoclonal antibody (mAb) biologics have been used to treat inflammatory bowel disease (IBD) for several years. Various classes of biologics for the treatment of IBD exist and include cytokine blockers and integrin blockers. Within these classes are mAbs that target different proinflammatory proteins such as tumor necrosis factor-alpha (TNF-alpha), interleukin 12 and 23 (IL-12, IL-23), and inte...
Biologics have been commonly prescribed as therapies for inflammatory bowel disease (IBD) since the late 1990s. However, research demonstrates that not all individuals respond to the first biologic taken and many lose response over time1. As a result, there is a great need to explore the immunogenicity of IBD biologics. Studies indicate that measuring drug levels, free anti-drug antibodies, and...
Nobel Prize winning British chemist Dr. Dorothy Hodgkin significantly contributed to unraveling the secrets of diabetes mellitus. She is considered a founder of X-ray crystallography, a technique used to discern the structures of organic biomolecules. Dorothy Hodgkin’s discovery of insulin's 3D structure paved the way for many scientific breakthroughs in diabetes research for years to follow. I...
[playlist images="false" artists="false" tracklist="false" ids="4600"]
A growing amount of research demonstrates that communication between the gut microbiota and liver is vital for the regulation of energy metabolism1,2. As a result, scientists are further exploring the relationship between the gut microbiota and gut-liver crosstalk to better understand metabolic diseases such as non-alcoho...
